Gastrointestinal Cancers

Expert faculty review and share their insights and perspectives on key findings in gastrointestinal cancers presented at the 2022 ASCO Annual Meeting.

Share

Program Content

Activities

  • ASCO 2022 GI Cancers
    Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2022 ASCO Annual Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 31, 2022

    Expires: August 30, 2023

Activities

CheckMate 142: 5-Yr Update
CheckMate 142: 5-Yr Follow-up With Nivolumab ± Ipilimumab for MSI-H/dMMR Metastatic CRC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

HERB: T-DXd for BTC
HERB: Single-Arm Phase II Trial of Trastuzumab Deruxtecan for Unresectable or Recurrent HER2-Expressing Biliary Tract Cancers
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

CONKO-007: CRT vs CT
CONKO-007: Chemoradiotherapy vs Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

CheckMate 648: Expanded Analysis
CheckMate 648: Expanded Analysis of First-line Nivolumab + CT vs Nivolumab/Ipilimumab vs CT in Advanced Esophageal Squamous Cell Carcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

HIMALAYA: PRO Analysis
HIMALAYA: Patient-Reported Outcomes for Patients With Unresectable Hepatocellular Carcinoma Receiving Durvalumab ± Tremelimumab
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

TOPAZ-1: PRO Data
TOPAZ-1: Patient-Reported Outcomes From the Phase III Placebo-Controlled Trial of Durvalumab + Gemcitabine + Cisplatin for Advanced Biliary Tract Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

PARADIGM
PARADIGM: Panitumumab + mFOLFOX6 vs Bevacizumab + mFOLFOX6 as First-line Treatment for mCRC With Wild-Type RAS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

TRIPLETE
TRIPLETE: Phase III Trial of First-line mFOLFOXIRI + Panitumumab vs mFOLFOX6 + Panitumumab in RAS/BRAF Wild-Type mCRC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

CAIRO5
CAIRO5: FOLFOXIRI + Bevacizumab vs FOLFOX/FOLFIRI + Bevacizumab in Patients With Initially Unresectable Colorectal Liver Metastases and Right-Sided and/or RAS/BRAFV600E-Mutated Primary Tumors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

Dostarlimab in dMMR Rectal Cancer
Phase II Study of Dostarlimab in Locally Advanced, Mismatch Repair–Deficient Rectal Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2022

Expires: June 13, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.